Brought to you by 
Moderna and Merck team up again, this time in oncology; Merck exercises option for mRNA-4157
03 Feb 2023
Executive Summary
Building on a successful partnership that began last year, Moderna Therapeutics LLC and Merck & Co. Inc. joined forces again, this time to develop mRNA-based personalized cancer vaccines that could be complementary to Merck's anti-PD-1 antibody therapy Keytruda.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Moderna and Merck team up again, this time in oncology; Merck exercises option for mRNA-4157
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice